Search

Your search keyword '"SECURITIES LAW"' showing total 284,484 results
Start Over Descriptor "SECURITIES LAW"

Refine your results

more »

more »

more »

more »

more »

more »

more »
284,484 results on '"SECURITIES LAW"'

1. Under the Private Securities Litigation Reform Act's Pleading Requirements for Securities Fraud Claims, How Should Allegations About Internal Company Documents and Expert Opinions Be Analyzed?

Author

Couture, Wendy Gerwick

Subjects
Lawsuit/litigation, Securities fraud, Securities law, Actions and defenses, NVIDIA Corp. -- Officials and employees, United States. Securities and Exchange Commission -- Officials and employees, Private Securities Litigation Reform Act of 1995
Abstract

CASE AT A GLANCE The Court will consider how the Private Securities Litigation Reform Act's heightened pleading standards apply to the securities fraud elements of scienter and falsity. The Court will address how much detail plaintiffs must allege about the contents of internal company documents in order to plead a strong inference of scienter based on an alleged mismatch between those documents and the company's public statements. The Court will also address how much weight courts should give to an expert's opinion about the falsity of a company's statements when assessing whether plaintiffs have pleaded particularized facts in support of falsity., Issues 1. Must plaintiffs seeking to allege scienter under the Private Securities Litigation Reform Act (PSLRA) based on allegations about internal company documents plead with particularity the contents of those [...]

Published
2024

2. Must a Company Disclose to Investors That a Risk Has Already Occurred, Even if There Is No Known Risk of Future Business Harm?

Author

Weisenfeld, David

Subjects
Facebook (Online social network), Publicly held corporations, Investor relations, Securities law, Fraud, Meta Platforms Inc., Cambridge Analytica, Amalgamated Bank, United States. Securities and Exchange Commission
Abstract

CASE AT A GLANCE This dispute centers on whether securities law requires a publicly traded company to pay the price for omitting information on a risk disclosure form. In warning investors about hypothetical risks on risk disclosure forms, does the company have to reveal past events?, Introduction The Supreme Court has decided to wade into a multibillion-dollar shareholder lawsuit that accuses Facebook's parent company, Meta, of fraud. The case explores how far a company's duty extends [...]

Published
2024

3. SEC rule confusion continues to put CISOs in a bind a year after a major revision

Subjects
Financial disclosure -- Laws, regulations and rules, Independent regulatory commissions -- Laws, regulations and rules, Securities law, Internet -- Safety and security measures, Cyberterrorism -- Laws, regulations and rules, Government regulation, Internet security, Computers
Abstract

Confusion around when and how to report cybersecurity breaches continues to plague companies a year after revised US Securities and Exchange Commission (SEC) https://www.sec.gov/files/rules/final/2023/33-11216.pdf came into effect, experts say. As [...]

Published
2025

4. What CISOs need to know about the SEC’s breach disclosure rules

Subjects
United States. Securities and Exchange Commission, Publicly held corporations, Financial disclosure, Independent regulatory commissions, Securities law, Internet -- Safety and security measures, Internet security, Computers
Abstract

The US Securities and Exchange Commission’s (SEC) breach disclosure rules have placed increased responsibility on the CISOs of publicly traded companies in the reporting of cybersecurity incidents and risks. The [...]

Published
2024

5. Do minority shareholder protection laws benefit investors? Evidence from a natural experiment on cross-listed firms

Author

Lin, Wei

Subjects
Investor relations -- Laws, regulations and rules, Corporate governance -- Laws, regulations and rules, Securities law, Emerging markets -- Laws, regulations and rules, Boards of directors -- Laws, regulations and rules, Government regulation, Business, international, International relations, Transportation industry
Abstract

Good corporate governance practices are not universal. Unlike practices in institutional settings in developed countries, which have attracted most scholarly attention, corporate governance practices in emerging economies lean towards addressing principal-principal conflicts that stem from concentrated ownership. The study employs a difference-in-differences panel data design with matched samples of Chinese firms cross-listed in mainland China and Hong Kong (China) and of those listed only in Hong Kong (China) based on propensity score matching. It thus adopts a natural experimental setting--the promulgation of China's Revised Securities Law in March 2020 --to pinpoint whether and how legal revisions of investor protection laws can really benefit investors. The findings show that independent directors in cross-listed firms turn over significantly more than those in firms listed only in Hong Kong (China). Also, it suggests that firms mainly replace departed directors with new directors from similar demographics. Furthermore, the study observes no evidence of significant changes in board independence in the short run. The findings suggest that policymakers should mind unintended consequences beyond the intended outcomes of the legal reforms on corporate governance, particularly the potential disproportionate impacts on smaller firms. Keywords : China, corporate governance, cross-listed firms, emerging economy, independent director, legal reforms, principal-principal conflicts JEL classification codes : G34, G38, K22, K40, P26, P52, 1. Introduction One core theme of the corporate governance literature is the mechanisms that protect shareholder interests. Adopting the classic agency theory (Eisenhardt, 1989; Fama and Jensen, 1983; Jensen and [...]

Published
2024

7. Xtl Biopharmaceuticals Ltd Files SEC Form 6-K, Report of Foreign Issuer [Rules 13A-16 And 15D-16]: (Dec. 30, 2024)

Subjects
Securities industry, Biological products industry, Biopharmaceutics, Securities law, Physical fitness, Securities industry, XTL Biopharmaceuticals Ltd., United States. Securities and Exchange Commission
Abstract

2025 JAN 18 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- According to news reporting originating from Washington, D.C., by NewsRx journalists, a [...]

Published
2025

19. Quantum Biopharma Ltd. Files SEC Form 6-K, Report of Foreign Issuer [Rules 13A-16 And 15D-16]: (Dec. 20, 2024)

Subjects
United States. Securities and Exchange Commission, Biological products industry, Securities law, Physical fitness, Securities industry, Securities industry, Health
Abstract

2025 JAN 11 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- According to news reporting originating from Washington, D.C., by NewsRx journalists, a [...]

Published
2025

22. Nok Therapeutics, Inc. Files SEC Form 1-A/A, Offering Statement [Regulation A]: (Dec. 23, 2024)

Subjects
United States. Securities and Exchange Commission -- Laws, regulations and rules, Securities law, Physical fitness -- Laws, regulations and rules, Government regulation, Health
Abstract

2025 JAN 11 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- According to news reporting originating from Washington, D.C., by NewsRx journalists, a [...]

Published
2025

25. Lakeshore Biopharma Co., Ltd. Files SEC Form 6-K, Report of Foreign Issuer [Rules 13A-16 And 15D-16]: (Dec. 19, 2024)

Subjects
United States. Securities and Exchange Commission, Biological products industry, Securities law, Physical fitness, Securities industry, Securities industry, Health
Abstract

2025 JAN 11 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- According to news reporting originating from Washington, D.C., by NewsRx journalists, a [...]

Published
2025

28. Cosciens Biopharma Inc. Files SEC Form 6-K, Report of Foreign Issuer [Rules 13A-16 And 15D-16]: (Dec. 23, 2024)

Subjects
United States. Securities and Exchange Commission, Biological products industry, Securities law, Physical fitness, Securities industry, Securities industry, Health
Abstract

2025 JAN 11 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- According to news reporting originating from Washington, D.C., by NewsRx journalists, a [...]

Published
2025

29. Connect Biopharma Holdings Ltd Files SEC Form 6-K, Report of Foreign Issuer [Rules 13A-16 And 15D-16]: (Dec. 23, 2024)

Subjects
United States. Securities and Exchange Commission, Biological products industry, Securities law, Physical fitness, Securities industry, Securities industry, Health
Abstract

2025 JAN 11 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- According to news reporting originating from Washington, D.C., by NewsRx journalists, a [...]

Published
2025

34. Pou Chen announces monthly sales for December 2024

Subjects
Stock Exchange of Hong Kong Ltd., Securities law
Abstract

Key Highlight: * Baoding Industries released its revenue figures for December 2024. Original Press Release: Jan. 10 -- Pou Chen Corporation issued the following news release: Pou Chen Industrial Co., [...]

Published
2025

41. Nok Therapeutics, Inc. Files SEC Form 1-A/A, Offering Statement [Regulation A]: (Dec. 17, 2024)

Subjects
Government regulation, Securities law, Physical fitness -- Laws, regulations and rules, United States. Securities and Exchange Commission -- Laws, regulations and rules
Abstract

2025 JAN 4 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- According to news reporting originating from Washington, D.C., by NewsRx journalists, a [...]

Published
2025

46. Lakeshore Biopharma Co., Ltd. Files SEC Form 6-K, Report of Foreign Issuer [Rules 13A-16 And 15D-16]: (Dec. 12, 2024)

Subjects
Securities industry, Biological products industry, Securities law, Physical fitness, Securities industry, United States. Securities and Exchange Commission
Abstract

2025 JAN 4 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- According to news reporting originating from Washington, D.C., by NewsRx journalists, a [...]

Published
2025

48. Calidi Biotherapeutics, Inc. Files SEC Form S-1, General Form For Registration of Securities Under The Securities Act of 1933: (Dec. 12, 2024)

Subjects
Biological products industry, Securities law, Biological products, Physical fitness, United States. Securities and Exchange Commission
Abstract

2025 JAN 4 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- According to news reporting originating from Washington, D.C., by NewsRx journalists, a [...]

Published
2025

Catalog

Books, media, physical & digital resources
See catalog results